Table 2 Baseline parameters of treatment naive patients subgrouped by different manifestation revealed a significant decrease in cholesterol in hepatic patients.

ALT

139

f: -35 U/l

m: -50 U/l

101.9

(7-3743)

22

(10-140)

28.2 (17-272)

20

(7-168)

>0.001

AST

135

f: -35 U/l

m: -50 U/l

76.9

(13-2106)

21.2

(6-58)

32

(19-108)

26.4

(11-102)

>0.001

Bilirubin

122

< 1.0 mg/dl

1.1

(0.2-39)

0.9

(0.1-3.8)

0.6

(0.2-1.4)

0.5

(0.2-0.9)

0.009

Albumin

103

30-50 g/l

41

(23-55)

45.2

(38-52)

43

(35-57)

46.3

(35-52)

0.001

TG

64

< 150 mg/dl

110

(33-888)

120

(63-200)

124

(40-249)

60

(59-100)

0.300

Cholesterol

70

< 200 mg/dl

158

(66-319)

194

(123-243)

186

(145-244)

195

(173-294)

0.004

HDL

14

>50 mg/dl

57

(42-76)

53

(48-77)

60

(56-64)

-

0.923

LDL

12

< 160 mg/dl

96

(63-218)

161

(156-166)

88

(81-95)

-

0.207

BMI

26

18.5-25 kg/m²

20.6

(14.9-24.5)

26.2

(20.3-30.8)

23.1

(14.8-28.6)

19.7

(19.7-19.7)

0.126